New approaches to the pharmacotherapy ... Antidepressants and anticonvulsants continue to be the first line treatment for the prevention of neuropathic pain. In these groups of substances, the ...

Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...

Researchers at Weill Cornell Medicine and the Burke Neurological Institute have made an exciting discovery—a new drug that ...

Neuropathic pain affects more than 20 million people in the U.S., and at least a quarter of these cases are puzzling for ...

The heterogeneous nature of the mechanisms underlying neuropathic pain complicates the selection of appropriate treatments for individual patients. Although systematic reviews have outlined the ...

If you’re new to CBD, it’s best to start with ... needed before experts can conclude CBD is an effective treatment for nerve-related pain. The CBD world is filled with a lot of claims and ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

low-dose antiviral treatment reduces the risk for potentially vision-damaging bouts of inflammation and infection, as well as pain, which occur when shingles affects the eye, according to new ...

Neuropathic pain is a severe clinical condition caused by damage to the nervous system. It often feels like a burning, ...

European researchers have mapped the most comprehensive phenotyping of neuropathic pain and identified ... improving patient quality of life and treatment outcomes. New research describes for ...

Recent evidence suggests that acupuncture can help relieve the pain caused by sciatica, a common condition in which the ...